Auto-generated from public data. Not the firm's stated position.
Segulah Medical Acceleration appears to focus on early-stage healthcare and life sciences companies in Northern Europe, with recent portfolio activity suggesting an emphasis on diagnostic and clinical monitoring technologies across biotech and healthtech sectors. The disclosed check size of €1.5M, €3.0M and concentration in Series A and Series B rounds indicate a strategy targeting companies transitioning from proof-of-concept to commercial validation.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Segulah Medical Acceleration's website.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.